Sanofi’s hemophilia A therapy BIVV-001 (efanesoctocog alfa) is set to present a challenge to Roche Holding AG/Genentech, Inc. ’s prophylaxis product Hemlibra (emicizumab) and could corner a sizeable chunk of the on-demand market for Factor VIII products if it surmounts its final clinical and regulatory hurdles.
The product has a US fast-track designation, and assuming positive results in the Phase III XTEND-1 trial expected in January...






